J
Jordi Rumià
Researcher at University of Barcelona
Publications - 117
Citations - 3206
Jordi Rumià is an academic researcher from University of Barcelona. The author has contributed to research in topics: Epilepsy & Deep brain stimulation. The author has an hindex of 29, co-authored 100 publications receiving 2863 citations. Previous affiliations of Jordi Rumià include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Effects of Bilateral Subthalamic Stimulation on Cognitive Function in Parkinson Disease
Montse Alegret,Carme Junqué,Francesc Valldeoriola,Pere Vendrell,Manuela Pilleri,Jordi Rumià,Eduardo Tolosa +6 more
TL;DR: Therapy with STN-DBS improves motor symptoms in PD without any clinically relevant neuropsychological deterioration.
Journal ArticleDOI
Levodopa Withdrawal After Bilateral Subthalamic Nucleus Stimulation in Advanced Parkinson Disease
José Luis Molinuevo,Francesc Valldeoriola,Eduardo Tolosa,Jordi Rumià,Josep Valls-Solé,Héctor Roldán,Enric Ferrer +6 more
TL;DR: Bilateral STN stimulation safely improves all parkinsonian symptoms, decreases or eliminates the need for levodopa, and ameliorates motor fluctuations and dyskinesias.
Journal ArticleDOI
Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease.
Pablo Martinez-Martin,Francesc Valldeoriola,Eduardo Tolosa,Manuela Pilleri,José Luis Molinuevo,Jordi Rumià,Enric Ferrer +6 more
TL;DR: STN‐DBS significantly improves important aspects of QoL in patients with advanced Parkinson's disease, as measured by the PDQ‐39, which shows significant benefit in the motor manifestations and complications of disease.
Journal ArticleDOI
Sleep symptoms and polysomnographic architecture in advanced Parkinson's disease after chronic bilateral subthalamic stimulation
TL;DR: In advanced Parkinson's disease, chronic STN-DBS is associated with subjective improvement in sleep quality, probably through increased nocturnal mobility and reduction of sleep fragmentation.
Journal ArticleDOI
Bilateral subthalamic stimulation monotherapy in advanced Parkinson's disease: long-term follow-up of patients.
Francesc Valldeoriola,Manuela Pilleri,Eduardo Tolosa,José Luis Molinuevo,Jordi Rumià,Enric Ferrer +5 more
TL;DR: STN‐DBS is useful in the treatment of advanced PD and in some patients it is possible to maintain this therapy alone in the long term with the additional benefit of avoiding motor fluctuations and dyskinesias.